본문으로 건너뛰기
← 뒤로

The effect of botulinum toxin A in children with non-neurogenic therapy-refractory dysfunctional voiding - A systematic review.

Journal of pediatric urology 2024 Vol.20(2) p. 211-218 피인용 1회 🌐 cited 11 🔓 OA Botulinum Toxin and Related Neurolog
TL;DR BTX-A could be a safe and effective treatment option for therapy-refractory DV in children by reducing PVR, UTIs and incontinence and the synergistic effect of BTX-A and urotherapy should be emphasized in future management.
📈 연도별 인용 (2024–2026) · 합계 10
OpenAlex 토픽 · Botulinum Toxin and Related Neurological Disorders Cardiovascular Syncope and Autonomic Disorders Urinary Bladder and Prostate Research

Hoelscher SAA, de Angst IB, Buijnsters ZA, Bramer WM, Akkermans FW, Kuindersma ME, Scheepe JR, Hoen LA'

관련 도메인

📝 환자 설명용 한 줄

BTX-A could be a safe and effective treatment option for therapy-refractory DV in children by reducing PVR, UTIs and incontinence and the synergistic effect of BTX-A and urotherapy should be emphasize

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 연구 설계 systematic review

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA S.A.A. Hoelscher, Isabel B. de Angst, et al. (2024). The effect of botulinum toxin A in children with non-neurogenic therapy-refractory dysfunctional voiding - A systematic review.. Journal of pediatric urology, 20(2), 211-218. https://doi.org/10.1016/j.jpurol.2023.10.034
MLA S.A.A. Hoelscher, et al.. "The effect of botulinum toxin A in children with non-neurogenic therapy-refractory dysfunctional voiding - A systematic review.." Journal of pediatric urology, vol. 20, no. 2, 2024, pp. 211-218.
PMID 38135586

Abstract

[INTRODUCTION] Dysfunctional voiding (DV) is a habitual voiding disorder caused by involuntary contraction or non-relaxation of the external urethral sphincter (EUS) during voiding. This contraction causes high post-void residuals (PVR), urinary incontinence and urinary tract infections (UTIs). Various treatments for DV are available, but some children do not respond. Intersphincteric botulinum toxin-A (BTX-A) may be a possible treatment for therapy-refractory children with DV.

[OBJECTIVE] The aim of this systematic review is to summarize the effects and safety of intersphincteric BTX-A as a treatment for therapy-refractory DV in children.

[METHODS] A systematic search in Embase, MEDLINE, Cochrane, and Web of Science databases was performed. Studies reporting on the usage of intersphincteric BTX-A as a treatment for DV in children were included. Data on PVR, maximum flow rate (Qmax), repeat injections and complications were extracted.

[RESULTS] From a total of 277 articles, five cohort studies were identified, reporting on 78 children with DV of whom 53 were female (68 %) and 25 were male (32 %). Sample sizes ranged from ten to twenty patients. Mean or median age at the time of intervention ranged from 8 to 10.5 years. Meta-analysis could not be performed due to lack of data. The narrative synthesis approach was therefore used to summarize the results. All studies showed significant decrease in PVR after BTX-A injection. Three studies showed a 33-69 % improvement on incontinence after BTX-A injection. Less UTIs were reported after treatment. A temporary increase in incontinence, UTIs and transitory numbness to the gluteus muscle were reported as side-effects.

[CONCLUSIONS] BTX-A could be a safe and effective treatment option for therapy-refractory DV in children by reducing PVR, UTIs and incontinence. Hereby, the synergistic effect of BTX-A and urotherapy should be emphasized in future management. Furthermore, this study identified gaps in current knowledge that are of interest for future research.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 2
해부 urinary tract scispacy 1
해부 urinary scispacy 1
합병증 voiding - scispacy 1
합병증 urethral sphincter scispacy 1
약물 UTIs → urinary tract infections scispacy 1
약물 BTX-A → botulinum toxin-A scispacy 1
약물 [CONCLUSIONS] BTX-A scispacy 1
약물 botulinum toxin A C0006050
botulinum toxin type A
scispacy 1
약물 [INTRODUCTION] Dysfunctional voiding scispacy 1
질환 gluteus muscle scispacy 1
질환 habitual voiding disorder scispacy 1
질환 urinary incontinence C0042024
Urinary Incontinence
scispacy 1
질환 urinary tract infections C0042029
Urinary tract infection
scispacy 1
질환 UTIs → urinary tract infections C0042029
Urinary tract infection
scispacy 1
질환 incontinence C0021167
Incontinence
scispacy 1
질환 numbness C0020580
Hypesthesia
scispacy 1
기타 botulinum toxin-A scispacy 1
기타 PVR → post-void residuals scispacy 1
기타 botulinum toxin A scispacy 1
기타 children scispacy 1

MeSH Terms

Humans; Botulinum Toxins, Type A; Child; Urination Disorders; Neuromuscular Agents; Treatment Outcome

📑 인용 관계

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문